We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

By LabMedica International staff writers
Posted on 23 Nov 2021
Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. More...
It frequently results in and is the most common cause of hyperthyroidism and it also often results in an enlarged thyroid.

Thyroid-stimulating hormone (TSH) receptor (TSHR) autoantibodies (TRAbs) are pathognomonic of GD and are detected in the serum of approximately 98% of patients with untreated GD. The specific and sensitive detection of thyroid-stimulating immunoglobulin (TSI) from other types of TRAbs is becoming increasingly important for the diagnostic accuracy of the Graves’ hyperthyroidism and of the extrathyroidal manifestations of GD.

Medical Laboratorians at the Shanghai Medical College (Shanghai, China) and their colleagues recruited 559 patients in the period between October 2020 and February 2021. There were 166 GD patients, 81 patients of whom were untreated GD, 393 patients with other thyroid diseases including 79 patients with Hashimoto's thyroiditis, 103 patients with thyroid nodules, 96 patients with hypothyroidism, 59 patients with nontoxic goiter, and 56 patients with thyroid cyst. In addition, 20 euthyroid healthy subjects were recruited as normal controls.

The team evaluated the analytical and clinical performance of two immunoassays for diagnosis of Graves’ disease (GD): the Immulite thyroid-stimulating immunoglobulin (TSI, Siemens Healthcare, Erlangen, Germany), and the Elecsys Anti-TSH receptor (TSHR), assay (Roche Diagnostics, Mannheim, Germany). The Immulite TSI assay is a chemiluminescence immunoassay with the clinical decision point of 0.55 IU/L. The Roche Elecsys Anti-TSHR assay is a competitive assay using electrochemiluminescence detection.

The investigators reported that the repeatability and intermediate imprecision coefficient of variation (CV%) of the TSI assay were 3.8% and 4.1% at 0.95 IU/L, and 3.5% and 3.6% at 19.5 IU/L, respectively. The assays were linear over a range 0.27–38.5 IU/L. There was a high correlation between the quantitative results of the two methods. The cut-off value obtained by ROC analysis for TSI assay was 0.7 IU/L with sensitivity of 93.7% and specificity of 85.1%. An overall qualitative agreement of 91.5% between two methods was observed. Among 44 patients with discordant qualitative results, the TSI assay provided more satisfactory results consistent with clinical diagnoses.

The authors concluded that the Immulite TSI assay specifically measured the pathogenic antibody of GD and exhibited excellent analytical performance. The Immulite TSI assay may be of great value for the clinical diagnosis of GD. The study was published on November 11, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Shanghai Medical College
Siemens Healthcare
Roche Diagnostics



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Portable Electronic Pipette
Mini 96
New
Gold Member
Collection and Transport System
PurSafe Plus®
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Pathology

view channel
Image: The new system allows surgeons to identify genotyping of brain tumors and determine optimal resection margins during surgery (Photo courtesy of Nagoya University)

New Technique Detects Genetic Mutations in Brain Tumors During Surgery within 25 Minutes

Determining the genetic profile of brain tumors during surgery is crucial for improving patient outcomes, but conventional analysis methods can take up to two days, delaying critical decisions.... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.